Probiotics with uric acid reducing activity, composite probiotic agent and application of probiotics and composite probiotic agent
By developing complex probiotic agents, Lentilactobacillus buchneri strain ZD62 and Bacillus fermentation ZD103 degrade purine nucleosides and inhibit xanthine oxidase, the problem of adverse reactions in existing drugs was solved, and effective relief and safety of hyperuricemia was achieved. therapeutic effect.
Patent Information
- Application Number
- CN202410991998.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-07-05
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-23
AI Technical Summary
There are adverse reactions and limited types of drugs used to treat hyperuricemia and gout, so we seek an auxiliary treatment with mild, non-toxic side effects.
A complex probiotic agent, including Lentilactobacillus buchneri strain ZD62 and Bacillus fermented fermented ZD103, was developed, which can degrade purine nucleosides to hypoxanthine, guanine and adenine, inhibit the activity of xanthine oxidase, and reduce the conversion of purine to uric acid. , and promote uric acid excretion by improving intestinal microbial composition.
This compound probiotic significantly reduced the serum uric acid level in hyperuricemia mice, relieved kidney damage and inflammatory response, and had good tolerance of artificial intestinal fluid and safety performance.
Smart Images

Figure CN118956653A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of probiotics and their application, and particularly relates to probiotics with uric acid lowering activity, a composite probiotic agent and their application. Background Art
[0002] Hyperuricemia (HUA) is a metabolic disorder characterized by high blood uric acid levels. Currently, about one-quarter of men and one-tenth of women suffer from asymptomatic or symptomatic hyperuricemia, the latter of which is called gout. As the incidence of hyperuricemia and gout increases year by year and becomes younger, hyperuricemia is considered the fourth important risk factor after the "three highs" of hypertension, hyperlipidemia and diabetes. There are many factors affecting hyperuricemia and gout, including genetics, age, gender, social and economic factors; excessive consumption of purine-rich foods such as meat, seafood, alcohol and sugary drinks; and other metabolic syndromes, such as hypertension, abnormal lipid / sugar metabolism and chronic kidney disease. The pathogenesis of hyperuricemia is complex and unclear. It is generally believed that its occurrence is mainly caused by increased uric acid production and (or) decreased excretion of uric acid in the body, which leads to increased blood uric acid levels. At present, clinical drug treatment for hyperuricemia mainly focuses on reducing uric acid production or promoting uric acid metabolism. Corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, allopurinol, febuxostat, benzbromarone, etc. are the first-line drugs for the treatment of acute gout. However, long-term use of such drugs is often accompanied by some adverse reactions. For example, during the treatment with allopurinol, patients usually experience rashes, gout attacks, gastrointestinal symptoms, elevated liver enzymes, blood abnormalities, and drowsiness. Other commonly used clinical drugs such as febuxostat and benzbromarone also have serious side effects. At present, the types of drugs used to treat hyperuricemia and gout are limited and their adverse reactions cannot be ignored. Therefore, it is of great significance to seek a mild, non-toxic and side-effect-free way to effectively relieve or assist in the treatment of hyperuricemia.
[0003] Lactic acid bacteria are safe, non-toxic, and edible. Their effects and pathways on hyperuricemia have been reported in recent years. Traditional fermented foods are rich in lactic acid bacteria, yeast, Aspergillus and other microorganisms, and are a huge treasure trove for the discovery of probiotic strains. Jiangshui and kefir grains are traditional fermented foods in my country, which contain a wealth of beneficial microorganisms, especially lactic acid bacteria. It is expected that natural probiotic strains with excellent characteristics can be isolated.
[0004] Chinese patent document CN 113215012A (application number: 202010932017.6) discloses a probiotic strain, composition and application thereof for lowering blood uric acid. The Lactobacillus reuteri disclosed in the patent document can degrade nucleotides and nucleosides, the precursors of uric acid, and has the effect of lowering the serum uric acid level in rats with hyperuricemia, but there is no report on inhibiting the activity of xanthine oxidase.
[0005] Although there are reports in the prior art that lactic acid bacteria have the effect of lowering uric acid, the effects of different strains vary significantly. It is of great significance to research and develop uric acid-lowering probiotic strains with excellent characteristics. Summary of the invention
[0006] In view of the deficiencies of the prior art, the present invention provides probiotics with uric acid-lowering activity, a composite probiotic agent and applications thereof.
[0007] The technical solution of the present invention is as follows:
[0008] A Lentilactobacillus buchneri strain ZD62 was deposited in the China Center for Type Culture Collection on March 14, 2024, with the deposit address being Wuhan University, Wuhan, China, and the deposit number being CCTCC NO: M2024469.
[0009] A composition comprising the above-mentioned Lentilactobacillus buchneri strain ZD62.
[0010] A composite probiotic preparation comprising Lentilactobacillus buchneri strain ZD62 and Bacillus fermentans ZD103.
[0011] Use of the above-mentioned Lentilactobacillus buchneri strain ZD62, composition or composite probiotic in any of the following items:
[0012] (1) Use in the preparation of drugs for preventing and / or treating hyperuricemia.
[0013] (2) Use in the preparation of drugs for preventing and / or treating gout.
[0014] (3) Use in the preparation of drugs for preventing and / or treating inflammation caused by hyperuricemia.
[0015] (4) Use in the preparation of drugs for preventing and / or treating liver damage caused by hyperuricemia.
[0016] (5) Use in the preparation of drugs for preventing and / or treating kidney damage caused by hyperuricemia.
[0017] (6) Application in the preparation of XOD inhibitors.
[0018] Application of fermentative mucobacterium ZD103 in any of the following:
[0019] (1) Use in the preparation of drugs for preventing and / or treating hyperuricemia.
[0020] (2) Use in the preparation of drugs for preventing and / or treating gout.
[0021] (3) Use in the preparation of drugs for preventing and / or treating inflammation caused by hyperuricemia.
[0022] (4) Use in the preparation of drugs for preventing and / or treating liver damage caused by hyperuricemia.
[0023] (5) Use in the preparation of drugs for preventing and / or treating kidney damage caused by hyperuricemia.
[0024] (6) Application in the preparation of XOD inhibitors.
[0025] The use of the above-mentioned Lentilactobacillus buchneri strain ZD62 or fermentative mucin Bacillus ZD103 in producing 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid and / or indolepyruvic acid.
[0026] A composition comprising 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid and / or indolepyruvic acid.
[0027] Preferably according to the present invention, the above composition is a XOD inhibitor composition.
[0028] Use of 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid, indolepyruvic acid or the above combination in any of the following:
[0029] (1) Use in the preparation of drugs for preventing and / or treating hyperuricemia.
[0030] (2) Use in the preparation of drugs for preventing and / or treating gout.
[0031] (3) Application in the preparation of XOD inhibitors.
[0032] The beneficial effects of the present invention include at least the following:
[0033] 1. The Lactobacillus buchneri ZD62 and the fermented mucobacterium ZD103 provided by the present invention have good uric acid-lowering properties. ZD62 and ZD103 can respectively achieve a degradation rate of 100% for inosine, guanosine and adenosine with a concentration of 0.5 g / L at 30 min and 90 min, and degrade them into corresponding hypoxanthine, guanine and adenine.
[0034] 2. The Lactobacillus buchneri ZD62 and Bacillus fermentans ZD103 provided by the present invention have good tolerance to artificial intestinal fluid, and their nucleoside degradation abilities can be maintained at more than 50% under artificial intestinal fluid conditions. Among them, the ZD62 strain has better tolerance, and its nucleoside degradation ability is almost unaffected.
[0035] 3. The metabolites of Lactobacillus buchneri ZD62 and Bacillus fermentans ZD103 provided by the present invention have a significant inhibitory effect on xanthine oxidase (XOD), and the effective ingredients that exert the inhibitory effect are acidic substances present in the extracellular metabolites of the strains, among which 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid and indolepyruvic acid in the metabolites have inhibition rates on XOD of 98.66±1.63%, 53.87±1.38% and 20.40±0.71%, respectively, which can effectively inhibit the activity of XOD and reduce the conversion of purine to uric acid.
[0036] 4. The Lactobacillus buchneri ZD62 and Bacillus fermentans ZD103 provided by the present invention have good indolepyruvic acid production capabilities, reaching 758±8.1 mg / L and 213±9.8 mg / L, respectively.
[0037] 5. The in vivo uric acid-lowering ability of Lactobacillus buchneri ZD62 and Bacillus fermentans ZD103 provided by the present invention was verified by constructing a hyperuricemia mouse model. The test results showed that in addition to a significant increase in serum uric acid levels in the model mice, there were also kidney damage, inflammatory response, and down-regulation of uric acid transporter gene transcription levels. After intervention treatment with ZD62 and ZD103, the serum uric acid levels of hyperuricemia mice decreased significantly, kidney damage was alleviated, inflammatory factors were reduced, and ZD6 2. ZD103 promotes the excretion of uric acid by regulating the expression of ABCG2 gene; in addition, ZD62 and ZD103 also changed the intestinal microbial composition of hyperuricemia mice, thereby increasing the overall microbial abundance in the mouse cecum, increasing the relative abundance of Firmicutes at the phylum level, decreasing the relative abundance of Bacteroidetes, and greatly increasing the proportion of Lactobacillus at the genus level; therefore, ZD62 and ZD103 can achieve the purpose of alleviating hyperuricemia by improving multiple physiological indicators.
[0038] 6. The Lactobacillus buchneri ZD62 and Bacillus fermentans ZD103 provided by the present invention are lactic acid bacteria separated from fermented food pulp water in Northwest China and Tibetan kefir grain yogurt. They are separated from food substances and have good safety performance. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 This is the liquid chromatography retention time diagram of inosine, guanosine and adenosine.
[0040] Figure 2 The standard curves of inosine (a), guanosine (b), and adenosine (c) are shown.
[0041] Figure 3 The colony and bacterial morphology of strains ZD62 and ZD103;
[0042] (a) ZD62 colony image; (b) ZD62 Gram microscopy image; (c) ZD62 scanning electron microscopy image; (d) ZD103 colony image; (e) ZD103 Gram microscopy image; (f) ZD103 scanning electron microscopy image.
[0043] Figure 4 This is a diagram of nucleoside degradation by ZD62 and ZD103;
[0044] (a) Degradation of mixed nucleosides by ZD62; (b) Degradation of mixed nucleosides by ZD103; (c) Degradation of single nucleosides by ZD62; (d) Degradation of single nucleosides by ZD103.
[0045] Figure 5 This is the peak diagram of the solution without probiotic nucleoside added;
[0046] Figure 6 Peak diagram of adding ZD62 nucleoside solution;
[0047] Figure 7 Peak diagram of adding ZD103 nucleoside solution;
[0048] Above Figure 5 , Figure 6 , Figure 7 Chinese: 1. Hypoxanthine 2. Inosine 3. Guanosine 4. Adenine 5. Adenosine 6. Guanine.
[0049] Figure 8 The graphs are the degradation rates of three nucleosides by ZD62 (a) and ZD103 (b) under artificial intestinal fluid conditions;
[0050] In the figure: a is the degradation diagram of three nucleosides by ZD62 under artificial intestinal fluid conditions; b is the degradation diagram of three nucleosides by ZD103 under artificial intestinal fluid conditions.
[0051] Fig. 9This is a diagram showing the effects of metabolites on XOD;
[0052] In the figure: (a) Effect of ZD62 and ZD103 metabolites on XOD; (b) Effect of intracellular and extracellular metabolites of ZD62 and ZD103 on XOD; (c) Effect of enzyme inactivation treatment of extracellular metabolites of ZD62 and ZD103 on XOD; (d) Effect of extracellular metabolites of ZD62 and ZD103 on XOD after pH adjustment.
[0053] Fig.10 are inhibition curves of different metabolites;
[0054] In the figure: (a) 1-hydroxy-2-naphthoic acid; (b) 3-indoleacrylic acid; (c) indolepyruvic acid.
[0055] Fig.11 Figure 2 shows the serum uric acid levels of mice in different treatment groups.
[0056] Fig.12 Figure 2 shows the levels of serum urea nitrogen (BUN) and serum creatinine (CRE) in mice in different treatment groups.
[0057] Fig.13 The figure shows the activity of XOD in the liver of mice in different treatment groups.
[0058] Fig.14 The graph shows the changes in the concentration of inflammatory factors in the serum of mice in different treatment groups.
[0059] Fig.15 Paraffin sections of the liver of mice in different treatment groups.
[0060] Fig.16 The kidney morphology and paraffin sections of mice in different treatment groups.
[0061] Fig.17 The relative expression of ABCG2 transporter in the jejunum and kidney of mice in different treatment groups. DETAILED DESCRIPTION
[0062] The technical solution of the present invention is further described below in conjunction with embodiments, but the scope of protection of the present invention is not limited thereto.
[0063] The contents not described in detail in the embodiments are based on the prior art in the art.
[0064] Lentilactobacillus buchneri strain ZD62 is abbreviated as Lactobacillus buchneri ZD62 or ZD62.
[0065] Fermentative Bacillus mucosa ZD103 can be purchased from the School of Bioengineering, Qilu University of Technology.
[0066] Example
[0067] The isolation, identification and performance test of lactic acid bacteria include the following:
[0068] 1 Materials and methods
[0069] 1.1 Isolation of lactic acid bacteria from traditional fermented foods
[0070] After the pulp water is homogenized, it is diluted in a gradient, and the yogurt is directly diluted in a gradient. The Tibetan kefir grains are inoculated into the whole fat sterilized milk at a ratio of 1:10, and then stand at 25℃ for 24h, and then the fermented kefir grains are washed with sterile water, and the kefir grains are re-inoculated into the milk in proportion, and the culture is continued according to the above method. Take 100mg of kefir grains and add them to a sterile centrifuge tube to grind them thoroughly, add 400μL of sterile saline to mix, and dilute them in a gradient.
[0071] 1.2 Screening of highly efficient nucleoside-degrading lactic acid bacteria
[0072] The preserved strain was activated in MRS liquid medium, cultured at 37°C, 180r / min for 24h, adjusted to OD600=1, and then inoculated in MRS liquid medium with 2% inoculum, cultured at 37°C, 180r / min for 48h; 2mL of culture solution was taken, centrifuged at 4°C, 8000r / min for 5min, and the bacteria were collected. The collected bacteria were resuspended and washed with sterile 0.9% NaCl aqueous solution, and then centrifuged at 4°C, 8000r / min for 5min to collect the bacteria; the bacteria were washed twice; 750μL of reaction solution was added to the washed bacteria, and the bacteria were resuspended and reacted in a shaking table at 37°C, 180r / min for 1h. At the end of the reaction, the reaction solution was quickly placed at 100°C for 5min to terminate the reaction, and centrifuged at 4°C, 12000r / min for 2min to collect the supernatant; the supernatant was filtered with a 0.22 micron microporous filter membrane, and the content of the three nucleosides was determined by HPLC. The chromatographic conditions were as follows: chromatographic column: Aligent ZorbaxSB-C18, column temperature: 35°C, flow rate: 1 mL / min, injection volume: 10 μL, detection wavelength: 260 nm, mobile phase: V (water): V (chromatographic methanol) = 95:5, pH: 4.7.
[0073] The degradation rates of the strains for the three nucleosides were calculated according to the formula.
[0074] Degradation rate (%) = (C mother liquor - C residue) / C mother liquor × 100%
[0075] Where C is mass concentration (g / L)
[0076] 1.3 Identification of highly efficient nucleoside-degrading strains
[0077] The strain was inoculated in MRS broth, cultured for 48 h, diluted and spread, and examined by Gram staining.
[0078] The fermentation broth was centrifuged to collect the bacteria, which were fixed with 2.5% glutaraldehyde (4°C, 4 h). After fixation, the bacteria were washed three times with physiological saline, and dehydrated with 30%, 50%, 70%, 90% and anhydrous ethanol respectively. Finally, the water was replaced with isoamyl acetate for 20 min. The treated bacteria were placed in a dryer for drying and placed on the sample stage of a scanning electron microscope, gold-sputtered, and observed and analyzed under a high vacuum environment.
[0079] The preliminary identification was carried out by combining the pentose fermentation experiment and the Bergey Manual of Bacterial Identification. The genome was extracted using a bacterial genomic DNA extraction kit, and the full-length sequence of the 16SrDNA gene was amplified using the bacterial universal primer 27F-1492R, and sequenced by Shanghai Sangon Biotechnology Co., Ltd. The obtained 16SrDNA sequence was compared with the known sequences on the NCBI website, and the phylogenetic tree was constructed using MEGA7.0 software.
[0080] 1.4 Degradation of nucleosides by strains and determination of their degradation products
[0081] The activated strains were reacted with 1.5 g / L inosine, adenosine solution and 0.7 g / L guanosine solution at 37 °C and 180 r / min for 2 h, and samples were taken at 10 min intervals to determine the degradation ability of lactic acid bacteria on nucleosides, and the degradation products of the three nucleosides were further determined. The maximum solubility of guanosine used in this experiment in water is 0.7 g / L. Inosine and guanosine were purchased from Shanghai MacLean Biochemical Technology Co., Ltd., and adenosine was purchased from Beijing Coolaibo Technology Co., Ltd.
[0082] 1.5 Determination of the ability of strains to degrade three nucleosides under artificial intestinal fluid conditions
[0083] Preparation of artificial intestinal fluid: Weigh 0.68g of potassium dihydrogen phosphate, add 50mL of water to dissolve, and adjust the pH to 6.8 with 0.1mol sodium hydroxide solution; take 1g of trypsin, add appropriate amount of water to dissolve, mix the two solutions, and dilute to 100mL with water. Weigh 0.5g of inosine, guanosine, and adenosine powders respectively and dissolve them in artificial intestinal fluid to prepare artificial intestinal fluid solution containing mixed nucleosides.
[0084] The activated ZD62 strain and the mixed nucleoside reaction solution dissolved in artificial intestinal fluid were reacted at 37°C and 180r / min for 60min, and the ZD103 strain was reacted for 120min. After the reaction, the reaction was terminated by boiling water for 5min, centrifuged at 4°C and 12000r / min for 2min, and the supernatant was collected. The supernatant was filtered with a 0.22-micron microporous filter membrane, and the contents of the remaining three nucleosides were determined by HPLC. The nucleoside solution dissolved in ultrapure water was used as a control.
[0085] 1.6 Obtaining strain metabolites
[0086] The ZD62 and ZD103 strains stored in the refrigerator were inoculated into 20 mL MRS broth medium at a volume ratio of 2%, cultured to OD600 = 1, and then transferred to 20 mL MRS broth at a volume ratio of 2%, 20 mL of the second generation logarithmic growth phase culture solution was taken into a centrifuge tube, centrifuged at 8000 r / min, 4 ° C for 10 min, and the supernatant was taken. After filtering through a 0.22 μm sterile filter, the extracellular metabolites of lactic acid bacteria were obtained; the bacterial precipitate after discarding the supernatant was washed twice with pH = 7.4 PBS buffer, and the bacterial precipitate was resuspended in 20 mL pH = 7.4 PBS buffer, and the cells were broken with an ultrasonic cell disruptor. MRS broth was purchased from Qingdao Haibo Biotechnology Co., Ltd.
[0087] Ultrasonic disruption conditions: In an ice bath, the power was 200W (working for 5s, stopping for 5s) and the pulse was disrupted for 20min. The liquid obtained after ultrasound was centrifuged at 4°C and 8000r / min for 10min, and the supernatant was collected and filtered through a 0.22μm sterile filter to obtain the intracellular metabolites of lactic acid bacteria. Take 100μL of metabolite sample into an EP tube, add 400μL of extraction solution (methanol: acetonitrile = 1: 1 (V / V), containing isotope-labeled internal standard mixture), vortex mix for 30s, ultrasonicate in an ice water bath for 10min, stand at 40°C for 1h, centrifuge the sample at 4°C and 12000rpm for 15min, take the supernatant and use Vanquish (Thermo Fisher Scientific) ultra-performance liquid chromatograph, and chromatographically separate the target compounds through Waters ACQUITY UPLCBEH Amide (2.1mm×50mm, 1.7μm) liquid chromatography column. Phase A of the liquid chromatography is an aqueous phase containing 25 mmol / L ammonium acetate and 25 mmol / L ammonia water, and phase B is acetonitrile. Sample plate temperature: 4°C, injection volume: 2 μL.
[0088] 1.7 Determination of the inhibitory effect of metabolites on XOD
[0089] X stands for xanthine, P stands for PBS, O stands for XOD, and M stands for metabolite.
[0090] The experimental design is as follows: the blank group (XP) is xanthine (800μL) + PBS (200μL, pH7.4); the control group (XPO) is xanthine (800μL) + PBS (80μL, pH7.4) + XOD (120μL); the experimental group (XMO) is xanthine (800μL) + metabolites (80μL) + XOD (120μL), XOD and metabolites / PBS are mixed and reacted at 37℃ for 30min, then xanthine is added and mixed thoroughly and reacted at 37℃ for 1h. After the reaction, the reaction tube is placed at 95℃ to inactivate the enzyme for 5min. After inactivation, the content of remaining xanthine in the system is detected by HPLC. In order to further determine the location of the metabolites and the effective components that play an inhibitory role, the metabolites were separated into intracellular and extracellular, the enzyme was inactivated at high temperature, and the pH value was adjusted.
[0091] 1.8 Molecular docking
[0092] Molecular docking can predict the binding mode of molecules by studying the intermolecular interactions, so it is widely used to analyze the binding mechanism of small molecule ligands and protein interactions and to screen inhibitors. The 3D structure of XOD was downloaded from the PDB database (https: / / www.rcsb.org / ), and the structure of acid substances was downloaded from the Chinese Medicine System Pharmacology Database and Analysis Platform. The XOD catalytic center includes a molybdenum pterin center, two iron-sulfur centers, and a flavin adenine dinucleotide, among which the molybdenum pterin center is the key site for xanthine oxidase to catalyze xanthine to produce uric acid. With Arg880 of the molybdenum pterin center as the center, XOD was docked and scored with the acid substances in the extracellular metabolites of Lactobacillus buchneri ZD62 and Lactobacillus fermentans ZD103.
[0093] 1.9 Verification of XOD inhibition effect
[0094] The metabolites screened out by molecular docking were verified. 1 g / L solutions of 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid, and indolepyruvic acid were prepared and diluted to different concentrations. 1-Hydroxy-2-naphthoic acid, 3-indoleacrylic acid, and indolepyruvic acid were purchased from Shanghai MacLean Biochemical Technology Co., Ltd. Referring to the method in 1.7, the metabolites were replaced with different concentrations of 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid, and indolepyruvic acid to verify the XOD inhibition effect.
[0095] Inhibition rate (%) = (experimental group - control group) / (blank group - control group) × 100%
[0096] 1.10 Determination of indolepyruvic acid content - High performance liquid chromatography (HPLC) method
[0097] Take ZD62, ZD103 and other lactic acid bacteria strains stored in the refrigerator and inoculate them into 20 mL MRS broth at a volume ratio of 2% respectively, culture until OD600 = 1, and then transfer them into 20 mL MRS broth at a volume ratio of 2%, culture at 37°C, 180 r / min for 48 hours. Extract indolepyruvic acid according to the method for obtaining strain metabolites in 1.6.
[0098] HPLC measurement of indolepyruvic acid was performed using an Agilent 1260 series HPLC (Agilent Technologies, USA) equipped with a UV-visible diode array detector. The chromatographic column was a ZORBAX SB-18 (5 μm, 4.6 × 150 mm), and the column oven was set at 35 °C throughout the separation. The mobile phase was 0.03% potassium dihydrogen phosphate solution and methanol. The injection volume was 10 μl, and the wavelength of the detector was set to 280 nm. 1.11 Animal Experiments
[0099] 1.11.1 Animal model construction
[0100] Since gout patients are mainly male, Kunming male mice were used in the experiment, and the animal hyperuricemia model was established by feeding a diet containing 4% potassium oxonate and 4% uric acid. Natural ventilation, free feeding and free drinking water were adopted, and the bedding was changed regularly.
[0101] 1.11.2 Animal Experiment Design
[0102] All mice were fed with commercial basal feed for 1 week and then randomly divided into 7 groups, 5 in each group. The mice's food and water intake were not restricted by any factors during the experiment. During the modeling period, one group was fed only with a basal diet, and the other six groups were fed with a high uric acid mouse diet containing 4% potassium oxonate and 4% uric acid. The serum uric acid content of the mice was measured after two consecutive weeks of modeling. Intervention treatment began in the third week. Except for the first group (blank group) which continued to be fed with a basal diet, the other five groups were given the following interventions:
[0103] The second group (ZD62) was gavaged 1x10 8 CFU / mL of Lactobacillus buchneri ZD62 0.5mL;
[0104] The third group (ZD103) was gavaged 1x10 8 CFU / mL of Lactobacillus fermentum ZD103 0.5mL;
[0105] The fourth group (ZD62+ZD103) was given intragastrically at a concentration of 1x10 8 0.5 mL of ZD62+ZD103 bacterial suspension with CFU / mL, the ratio of ZD62 to ZD103 was 1:1;
[0106] Group 5 (allopurinol) was intragastrically administered with allopurinol (5 mg / kg);
[0107] The sixth group (model group) was gavaged with normal saline;
[0108] All gavage treatments were performed once a day.
[0109] At the end of the animal experiment, according to the relevant provisions of animal ethics, the inventors used 1% sodium pentobarbital to anesthetize all mice, collected mouse blood by removing the eyeballs, and killed the mice at the same time. Fresh blood samples were left to stand at 37°C for 1 hour and centrifuged at 3000r / min for 10 minutes to obtain mouse serum. Mouse liver, kidney, intestine and serum specimens were collected in sterile PE tubes. Physiological tissue section samples were stored in 4% paraformaldehyde, and the remaining samples were stored at -80°C for later use.
[0110] 1.11.3 Analysis of Physiological Indexes of Mouse Blood and Tissues
[0111] The mouse liver and kidney fixed overnight in 4% paraformaldehyde were embedded in paraffin, and the tissue morphology was observed using an optical microscope after hematoxylin and eosin (H&E) staining.
[0112] ELISA kits were used to detect the anti-oxidative inflammation-related factors IL-18, IL-1β and TNF-α, a uric acid detection kit was used to detect mouse serum uric acid, and serum creatinine (CRE) and blood urea nitrogen (BUN) detection kits were used to detect the CRE and BUN contents in mouse serum.
[0113] Fresh frozen mouse livers were weighed, and 9 times the volume of normal saline was added as the homogenization medium at a ratio of 1:9, and an appropriate amount of liquid nitrogen was added. The livers were evenly ground with a handheld grinder, and the supernatant was collected by low-speed centrifugation at 3000 rpm / min for 10 min. Xanthine oxidase (XOD) in the livers of mice in different groups was determined using the XOD test kit produced by Nanjing Jiancheng Bioengineering Institute in strict accordance with the instructions.
[0114] 1.11.4 Analysis of uric acid transporter-related gene expression levels in mouse kidney and intestine
[0115] (1) Design and synthesis of primers for uric acid transporter-related genes
[0116] The upstream and downstream primers of the ABCG2 gene encoding the uric acid transporter and the standard internal reference β-actin were designed using the NCBI website and used for real-time fluorescence quantitative PCR (qPCR) amplification. All primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0117] Table 1 Primer sequences
[0118]
[0119] (2) Extraction and detection of mRNA in mouse kidney and intestinal tissues
[0120] Mouse kidneys and intestines frozen at -80°C were taken, and RNA was extracted from the kidney and intestinal tissues of mice in different treatment groups strictly according to the instructions of FastPure Cell / Tissue Total RNA Isolation Kit-BOX2 Kit (Nanjing Novozymes Biotech Co., Ltd.). The extracted RNA was measured by ultra-micro spectrophotometer to determine the A260 / A280 to determine the concentration and purity of the RNA.
[0121] (3) RNA reverse transcription
[0122] According to the operating steps provided by the HiScript III RT SuperMix for qPCR (+gDNAwiper) (R323) kit of Nanjing Novogene Biotechnology Co., Ltd., the extracted RNA was reverse transcribed into cDNA. The reverse transcription reaction system is as follows, see Table 2:
[0123] Table 2 Reverse transcription system
[0124]
[0125] (4) Real-time fluorescence quantitative PCR
[0126] The obtained cDNA was used as a template and the corresponding primers were used for qPCR amplification. The reaction system is shown in Table 3, and the qPCR reaction procedure is shown in Table 4.
[0127] Table 3 qPCR reaction system
[0128]
[0129]
[0130] Table 4 qPCR reaction procedure
[0131]
[0132] All samples were tested in triplicate, and β-actin gene was used as an internal reference. -ΔΔCt The relative expression of genes was analyzed by the method. The calculation formula is as follows: ΔCt = Ct target gene - Ct internal reference gene; ΔΔCt = ΔCt target gene in experimental group - ΔCt target gene in control group; relative expression = 2 -ΔΔCt .
[0133] 1.11.5 Analysis of mouse intestinal microbial diversity
[0134] Microbial genomic DNA from mouse cecal contents was extracted using the HiPure Soil DNA extraction kit (Magen, Guangzhou, China). The V3-V4 region of the 16srDNA gene was amplified by PCR using primers 341F and 806R. The quality of the amplicon was evaluated using 2% agarose gel, PCR product purification was performed using AMPure XP Beads (Beckman, CA, USA), quantification was performed using Qubit 3.0, and sequencing libraries were constructed using the Illumina DNA Prep Kit (Illumina, CA, USA). The raw data of the Illumina platform were filtered using FASTP (version 0.18.0), and the data obtained after filtration were analyzed using clean reads. The primer sequences are: 341F: CCTACGGGNGGCWGCAG SEQ ID NO.7; 806R: GGACTACHVGGGTATCTAAT SEQ ID NO.8.
[0135] 1.11.6 Data Analysis
[0136] All experimental data were expressed as mean ± standard deviation (SD), and the significant differences between the groups were obtained by One-Way ANOVA (single-factor analysis of variance), and the graphs were drawn using GraphPad software.
[0137] 2 Test results
[0138] 2.1 Establishment of three nucleoside standard curves
[0139] Under the established liquid phase conditions, the retention time of inosine is 4.334min, guanosine is 4.690min, and adenosine is 11.705min. The three nucleosides can be well separated under this liquid phase condition. Figure 1 , and a good linear relationship was shown between the concentrations of 0.1-0.5g. Figure 2 .
[0140] 2.2 Screening of efficient nucleoside-degrading strains
[0141] A total of 52 strains were isolated and purified from different traditional fermented foods. Six strains had degradation rates of inosine above 30%, and two strains had degradation rates of 60% and above, six strains had degradation rates of 30% and above for guanosine, and two strains had degradation rates of 60% and above, and 12 strains had degradation rates of adenosine above 30%, and three strains had degradation rates of 60% and above. Among them, the ZD62 strain could reduce the concentration of three nucleosides with a concentration of 0.5g / L to 0g / L in 60 minutes, with a degradation rate of 100%, and the ZD103 strain had degradation rates of three nucleosides with a concentration of 0.5g / L above 60% in 60 minutes. Subsequently, the strains ZD62 and ZD103, which have significant advantages in reducing nucleosides, were selected for in-depth research.
[0142] 2.3 Identification of highly efficient nucleoside-degrading strains
[0143] On the MRS plate, the colonies of ZD62 and ZD103 were round, milky white, with complete edges and smooth surfaces ( Figure 3 Middle a, Figure 3 (middle d). ZD62 Gram staining showed purple under microscopy ( Figure 3 b), ZD103 showed blue-purple color after Gram staining ( Figure 3 e), both strains are Gram-positive bacteria, and ZD62 and ZD103 are short rod-shaped under a scanning electron microscope, so the two strains are judged to be Gram-positive rods ( Figure 3 Middle c, Figure 3f). The results of the sugar fermentation experiment showed that the ZD62 strain could ferment maltose, sucrose, and raffinose to produce acid, and the ZD103 strain could ferment maltose, sucrose, raffinose, inulin, and lactose to produce acid. Combined with the Bergey Bacteria Identification Manual, it was determined that both ZD62 and ZD103 strains were lactobacilli. The 16SrDNA sequence of strain ZD62 is shown in SEQ ID NO.1, and the 16SrDNA sequence of strain ZD103 is shown in SEQ ID NO.2. The 16SrDNA sequences of the two strains were entered into the NCBI database for BLAST comparison, and it was found that the homology between strain ZD62 and Lentilactobacillus buchneri strain JCM 1115 reached 100%. The homology of strain ZD103 and Limosilactobacillus fermentum strain CIP 102980 reached 99.78%. According to the phylogenetic tree constructed by MEGA7 software, strain ZD62 and Lactobacillus buchneri belonged to the same branch and had the closest relationship. Therefore, the strain was determined to be a Lactobacillus buchneri strain and was named Lentilactobacillus buchneri strain ZD62, abbreviated as Lactobacillus buchneri ZD62 or ZD62. ZD103 and Limosilactobacillus fermentum belonged to the same branch and had the closest relationship. Therefore, the strain was determined to be a Lactobacillus buchneri strain and was named Lactobacillus buchneri strain ZD103, abbreviated as ZD103.
[0144] Lentilactobacillus buchneri strain ZD62 was deposited in the China Center for Type Culture Collection on March 14, 2024, with the deposit address being Wuhan University, Wuhan, China, and the deposit number being CCTCC NO: M 2024469.
[0145] 2.4 Degradation of nucleosides by strains and determination of their degradation products
[0146] Depend on Figure 4 It can be seen that Lactobacillus buchneri ZD62 can reduce the concentration of the three mixed nucleosides, all of which are 0.5g / L, to 0g / L within 30min ( Figure 4 a); fermentation of Lactobacillus mucilaginosus ZD103 can reduce the concentration of three mixed nucleosides of 0.5g / L to 0g / L at 90min ( Figure 4b). During the reaction of ZD62 and ZD103 with the mixed nucleoside solution, the two strains simultaneously reduced the concentrations of inosine, guanosine and adenosine, without any order of precedence. After increasing the concentration of a single nucleoside, it was found that Lactobacillus buchneri ZD62 could reduce the concentrations of inosine and adenosine, both of which were 1.5 g / L, to 0 g / L within 30 minutes, and could completely degrade guanosine, which was 0.7 g / L, in just 10 minutes ( Figure 4 c). The fermentation of Lactobacillus mucilaginosus ZD103 can completely degrade the inosine concentration of 1.5g / L in 100min, completely degrade the guanosine concentration of 0.7g / L in 40min, and completely degrade the adenosine concentration of 1.5g / L in 110min ( Figure 4 (d)
[0147] Depend on Figure 5 , Figure 6 , Figure 7 ( Figure 5 , Figure 6 , Figure 7 (in Chinese: 1. hypoxanthine 2. inosine 3. guanosine 4. adenine 5. adenosine 6. guanine) It can be seen that after ZD62 and ZD103 reacted with the three nucleosides respectively, as the peak areas of the three nucleosides decreased, three new products appeared, which were verified by HPLC to be hypoxanthine, guanine, and adenine, respectively, indicating that the mechanism by which ZD62 and ZD103 reduce purine nucleosides is to convert them into corresponding purine bases. Purine bases are less easily absorbed by the intestine than purine nucleosides, so ZD62 and ZD103 can reduce the production of uric acid by indirectly reducing the absorption of purine nucleosides by the intestine.
[0148] 2.5 Tolerance of highly efficient nucleoside-degrading strains to artificial intestinal fluid
[0149] The small intestine is the place where lactic acid bacteria exert their nucleoside degradation, and the intestinal fluid therein will have an adverse effect on the activity of lactic acid bacteria. Therefore, the inventors determined the nucleoside degradation ability of strains ZD62 and ZD103 in artificial intestinal fluid. Figure 8 As shown in Figure 2, the degradation rates of inosine, guanosine and adenosine by strain ZD62 in artificial intestinal fluid and in aqueous solution are basically the same ( Figure 8 a), that is, the ZD62 strain can also efficiently degrade the three nucleosides in artificial intestinal fluid; the degradation ability of the ZD103 strain on nucleosides in artificial intestinal fluid is significantly reduced, but the degradation rate of the three nucleosides is still maintained above 50% ( Figure 8 b), indicating that both strains have a certain tolerance to artificial intestinal fluid, but ZD62 has better tolerance. In summary, both ZD62 and ZD103 can be used as high-quality bacterial strain resources for the development of probiotic products for the prevention and treatment of hyperuricemia.
[0150] 2.6 Determination of the inhibitory effect of metabolites on XOD
[0151] like Fig. 9 As shown in a, the xanthine concentration of the XPO group was significantly lower than that of the blank group with only xanthine, indicating that XOD had good enzyme activity under this reaction condition. The xanthine concentration of the XMO group of the ZD62 and ZD103 strains was significantly higher than that of the XPO group, indicating that the metabolites of both strains inhibited the activity of XOD; the extracellular metabolites of both strains significantly inhibited the activity of XOD, but the intracellular metabolites of both strains had no significant inhibitory effect on XOD ( Fig. 9 b), indicating that the metabolites that inhibit XOD exist outside the strains; the extracellular metabolites of the two strains have an inhibitory effect on XOD regardless of whether the enzyme is inactivated ( Fig. 9 c), it is inferred that the inhibition of XOD by the extracellular metabolites of the strains is not caused by enzymes; the extracellular metabolites of the two strains were neutralized with sodium hydroxide to adjust the pH to 7, and it was found that the neutralized extracellular metabolites lost their inhibitory effect on XOD ( Fig. 9 d), it is judged that the inhibition of XOD by ZD62 and ZD103 may be caused by the acid substances therein. In summary, it is preliminarily determined that the acid substances present in the extracellular metabolites of the two strains play an inhibitory role in XOD.
[0152] 2.7 Molecular docking
[0153] According to the results of non-target metabolomics detection of fermentation broth, there are 382 substances including fatty acids, organic acids, amino acids, aromatic compounds, etc. in the fermentation broth of Lactobacillus brucelli ZD62, and 387 substances including fatty acids, organic acids, amino acids, aromatic compounds, etc. in the fermentation broth of Lactobacillus mucilaginosus ZD103. After screening, 52 acids are common in the metabolites of the two strains. These 52 acids were molecularly docked with XOD, and three substances with strong interaction with XOD (the larger the negative value, the stronger the interaction with XOD) were selected for verification. According to the docking results, 1-Hydroxy-2-naphthoic acid (1-hydroxy-2-naphthoic acid), 3-Indoleacrylic Acid (3-indoleacrylic acid), and Indolepyruvate (indolepyruvic acid) were finally selected for subsequent verification.
[0154] According to the interaction pattern diagram of 1-hydroxy-2-naphthoic acid and XOD, 1-hydroxy-2-naphthoic acid forms a hydrogen bond interaction force with the amino acid residue GLU1261 of XOD, and forms a hydrophobic interaction with the amino acid residues LEU1014 and VAL1011. According to the interaction pattern diagram of 3-indoleacrylic acid and XOD, hydrogen bond interaction and hydrophobic interaction are formed between 3-indoleacrylic acid and the amino acid residue ALA1079 of XOD. According to the interaction pattern diagram of indolepyruvic acid and XOD, indolepyruvic acid forms a hydrogen bond interaction with the amino acid residues GLY1260 and GLN1194 of XOD, and forms a hydrophobic interaction with the amino acid residue MET1038. The chemical bonds formed between these three substances and xanthine oxidase help small molecules to play a role, thereby producing a certain promotion or inhibition effect on the enzyme.
[0155] 2.8 Verification of XOD inhibition effect
[0156] It has been verified that 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid, and indolepyruvic acid have different degrees of inhibition on XOD within the concentration range of 0.1-1g / L ( Fig.10 ). Among them, the inhibition rate of 1-hydroxy-2-naphthoic acid reached the maximum at 0.8g / L (98.66±1.63%), showing a strong XOD inhibition ability; the inhibition rate of 3-indoleacrylic acid reached the maximum at 0.8g / L (53.87±1.38%), and when the concentration was higher than 0.8g / L, the inhibition rate began to decrease; the inhibition rate of indolepyruvic acid on XOD showed a trend of first increasing and then decreasing, and had no inhibitory effect on XOD when the concentration was lower than 0.5g / L. In the concentration range of 0.5-0.9g / L, the inhibition effect on XOD gradually increased with the increase of concentration, and reached the maximum inhibition rate at 0.9g / L (20.40±0.71%), which provided theoretical support for the conclusion that the metabolites of ZD62 and ZD103 inhibited the activity of XOD.
[0157] 2.9 Indolepyruvic acid production capacity of strains ZD62 and ZD103
[0158] Fermentation was carried out according to the fermentation method described in 1.6 Obtaining the metabolites of the strains, and the concentration of indolepyruvic acid in the fermentation broth of each strain was detected, see Table 5.
[0159] Table 5 Comparison of indolepyruvic acid production capacity of different lactic acid strains
[0160]
[0161]
[0162] 2.10 Analysis of physiological parameters of mouse blood and tissues
[0163] like Fig.11 As shown in the results, whether it is probiotic intervention or allopurinol treatment, the serum uric acid level of mice is significantly lower than that of the high uric acid model group (model group). Among them, allopurinol, which has the best effect in reducing blood uric acid, can reduce the serum uric acid content of hyperuricemia mice to 66.67±11.09μmol / L. The results of probiotic intervention show that the uric acid-lowering effect of ZD103 fermented mucobacterium is second only to allopurinol, which can reduce the uric acid level of hyperuricemia mice to 70.59±5.55μmol / L. The use of ZD62 strain alone only reduced the uric acid level of hyperuricemia mice to 117.65±10.38μmol / L, but when used in combination with ZD103, the effect of reducing serum uric acid is greatly improved, which can be reduced to 72.19±8.32μmol / L. The participation of ZD103 strain improved the effect of lowering uric acid, but because the bacterial count of ZD103 after the two strains were mixed was lower than the bacterial count when ZD103 was used alone, the uric acid lowering effect of ZD103 alone was better than that of the combined effect of the two strains.
[0164] BUN is a metabolic product of protein in the body. It will be reabsorbed in the renal tubules after being filtered through the glomeruli. CRE is an important substance produced by human muscle metabolism and mainly excreted through the glomeruli. To a certain extent, the degree of kidney damage caused by HUA can be measured by the levels of BUN and CRE in serum.
[0165] like Fig.12 As shown in the data, there was no significant difference in the serum BUN content between the mice in the model group and the mice in the Control group, but there were significant differences in the serum BUN content and CRE of the mice in the allopurinol group compared with other groups. It is speculated that the use of allopurinol caused certain damage to the mouse kidneys, thereby affecting the reabsorption of BUN and the excretion of CRE by the mouse kidneys; the serum CRE content of the mice in the model group was significantly higher than that in the Control group (P < 0.01), indicating that the excessive uric acid level in HUA mice affected the normal excretion of CRE by the glomeruli, resulting in an increase in the CRE content. After intervention treatment, the serum CRE content of the ZD62 + ZD103 group was significantly lower than that of the model group (P < 0.001), which indicates that the combined use of the two strains of ZD62 + ZD103 can effectively alleviate renal damage in hyperuricemia mice.
[0166] XOD in mouse liver is an important purine metabolic enzyme, which forms uric acid by oxidizing xanthine and hypoxanthine. Therefore, it is necessary to detect the changes of XOD after the increase of uric acid. Fig.13 As shown, except for the significantly decreased XOD activity in the liver of hyperuricemia mice in the ZD62 treatment group, there was no significant difference in XOD activity among mice in the other treatment groups, indicating that the extracellular metabolites of the ZD62 strain can effectively inhibit the activity of XOD.
[0167] like Fig.14 As shown in the results, the levels of IL-1β (P<0.05) and TNF-α (P<0.001) in the blood of mice in the model group were significantly higher than those in the control group, and there was no significant difference in the level of IL-18 in the blood of mice in the model group compared with that in the control group, indicating that the increase in uric acid levels caused an inflammatory response in mice to a certain extent.
[0168] When ZD62 and ZD103 were used together, they could significantly reduce the levels of IL-1β, IL-18, and TNF-α in the serum of hyperuricemia mice. When ZD103 was used alone, it could reduce the levels of IL-1β and IL-18 in the serum of hyperuricemia mice. These results indicate that probiotics can alleviate the inflammatory response caused by hyperuricemia to varying degrees, and the combined use of the two strains has a better effect.
[0169] like Fig.15 As shown in the figure, the nuclear staining of liver cells in the model group mice deepened, which indicated that a large amount of uric acid caused a certain burden on the mouse liver. The strains ZD62 and ZD103 alleviated the deepening of nuclear staining of liver cells. This result shows that Lactobacillus buchneri ZD62 and Lactobacillus fermentans ZD103 have a certain alleviating effect on liver damage caused by high uric acid.
[0170] Renal morphology showed that the kidneys of the mice in the model group were atrophic, and HE staining results showed that the kidneys of the mice in the model group had a large amount of inflammatory infiltration, loose cytoplasm, mild staining, and occasional suppurative lesions. Allopurinol group had a certain effect on alleviating the inflammatory infiltration and loose cytoplasm of the kidneys of hyperuricemia mice, but Fig.16 It can be seen that the kidneys of mice in the allopurinol group were significantly swollen, which indicates that the use of allopurinol caused some damage to the kidneys of mice. The ZD62, ZD103, and ZD62+ZD103 groups all significantly alleviated the inflammatory response of the kidneys of mice with high uric acid. Fig.16 It can be seen that after intervention treatment with ZD62, ZD103, and ZD62+ZD103, the inflammatory infiltration of the kidneys of mice was greatly reduced, the purulent lesions disappeared, and the cytoplasmic loosening was also well relieved. Among them, the effect of the ZD103 group was the most significant. This result shows that ZD62, ZD103, ZD62+ZD103, and allopurinol treatment can alleviate the renal inflammatory response caused by hyperuricemia in mice, but the use of allopurinol can cause renal damage to mice, so the comprehensive evaluation shows that the therapeutic effect of probiotics is better than that of allopurinol.
[0171] 2.10 Analysis of ABCG2 gene transcription levels in the jejunum and kidneys of mice in each group
[0172] Compared with the Control group, the relative gene expression of ABCG2 in the jejunum of the model group mice was significantly decreased (P < 0.01), indicating that the increase in serum uric acid levels in the model group mice was related to the inhibition of intestinal uric acid excretion mediated by ABCG2. Fig.17 As can be seen from Figure a, after the intervention treatment with lactic acid bacteria, the expression of ABCG2 gene in the ZD103 group and the ZD62+ZD103 group was significantly higher than that in the model group (P < 0.05), indicating that the combined use of ZD103 strain and ZD62+ZD103 strains can improve the down-regulation of ABCG2 gene in the jejunum of hyperuricemia mice to improve the ability of mice to excrete uric acid in the intestine, thereby reducing the uric acid level in hyperuricemia mice; Figure 17b shows that the relative expression level of ABCG2 gene in the kidney of the model group mice was significantly lower than that of the Control group (P < 0.001), indicating that the increase in serum uric acid level in the model group mice was partly due to the decreased expression of the transporter protein encoded by the ABCG2 gene in the kidney, which led to a decrease in the excretion of uric acid by the kidney. After different intervention treatments, the relative expression of ABCG2 gene in the kidney of mice in the ZD62+ZD103 group was significantly higher than that in the model group (P<0.001). This result shows that the combination of ZD62 and ZD103 can improve the ability of the kidneys of hyperuricemia mice to excrete uric acid to achieve the therapeutic effect of lowering uric acid. The inventors also found that ZD62 and ZD103 did not significantly improve the expression of ABCG2 gene in the kidneys of hyperuricemia mice when used alone, but the effect of combined use showed significant differences compared with that when used alone (P<0.001). It is inferred that the combined use of ZD62 and ZD103 is more effective in improving the excretion of uric acid in the kidneys of hyperuricemia mice.
Claims
1. A Lentilactobacillus buchneri strain ZD62, deposited in China Center for Type Culture Collection on March 14, 2024, with the deposit address being Wuhan University, Wuhan, China, and the deposit number being CCTCC NO: M 2024469.
2. A composition comprising the Lentilactobacillus buchneri strain ZD62 according to claim 1.
3. A composite probiotic comprising Lentilactobacillus buchneristrain ZD62 and fermentative mucin Bacillus ZD103 as claimed in claim 1.
4. Use of the Lentilactobacillus buchneristrain ZD62 according to claim 1, the composition according to claim 2 or the composite probiotic according to claim 3 in any of the following: (1) Use in the preparation of drugs for preventing and / or treating hyperuricemia; (2) Use in the preparation of drugs for the prevention and / or treatment of gout; (3) Use in the preparation of drugs for preventing and / or treating inflammation caused by hyperuricemia; (4) Use in the preparation of drugs for preventing and / or treating liver damage caused by hyperuricemia; (5) Use in the preparation of drugs for preventing and / or treating kidney damage caused by hyperuricemia; (6) Application in the preparation of XOD inhibitors.
5. Application of fermentative mucobacterium ZD103 in any of the following: (1) Use in the preparation of drugs for preventing and / or treating hyperuricemia; (2) Use in the preparation of drugs for the prevention and / or treatment of gout; (3) Use in the preparation of drugs for preventing and / or treating inflammation caused by hyperuricemia; (4) Use in the preparation of drugs for preventing and / or treating liver damage caused by hyperuricemia; (5) Use in the preparation of drugs for preventing and / or treating kidney damage caused by hyperuricemia; (6) Application in the preparation of XOD inhibitors.
6. Use of the Lentilactobacillus buchneri strain ZD62 according to claim 1 or the fermentative mucobacterium ZD103 according to claim 5 in producing 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid and / or indolepyruvic acid.
7. A composition comprising 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid and / or indolepyruvic acid.
8. The composition according to claim 7, characterized in that The composition is a XOD inhibitor composition.
9. Use of 1-hydroxy-2-naphthoic acid, 3-indoleacrylic acid, indolepyruvic acid or the composition according to claim 7 in any of the following: (1) Use in the preparation of drugs for preventing and / or treating hyperuricemia; (2) Use in the preparation of drugs for the prevention and / or treatment of gout; (3) Application in the preparation of XOD inhibitors.
Citation Information
Patent Citations
Lactobacillus pentosus and application thereof in preparation of medicine for preventing or treating hyperuricemia
CN116064331A
Phytobacterium plantarum for relieving hyperuricemia and compound and application thereof
CN116286534A
Blood uric acid level lowering agent
WO2011102310A1
Cited By
Lactobacillus buchneri complex microbial inoculant and application thereof
CN120966719A
Lactobacillus buchneri complex microbial inoculant and application thereof
CN120966719B
Salt-tolerant lactobacillus fermentum DHZK03 capable of degrading purine and uric acid and application thereof
CN121555363A
Lactobacillus buchneri and application thereof
CN121874059A
Lactobacillus buchneri with hypoglycemic activity and application of lactobacillus buchneri in fermented milk
CN122168474A
